The collaboration supports Pulse Biosciences’ planned first-in-human study of its pulsed-field ablation technology. Hayward, California-based Pulse develops a proprietary nanosecond pulsed-field ablation (nsPFA) cardiac catheter to treat AFib.
Pulse and CardioNXT plan for their partnership to integrate the nsPFA catheter and the CardioNXT iMap navigation and mapping system. This enables electrophysiologists to successfully visualize individual cardiac structures when using the integrated platforms. They can then place the catheter for circumferential ablations of targeted pulmonary veins in AFib treatment.
CardioNXT CEO Jerome Edwards said in a news release that Pulse’s nsPFA technology provides “a highly differentiated” solution. He said integrating systems …